Imaging
in Drug Development
Jeffrey L. Evelhoch, Ph.D., and John R.
Griffiths, M.B.B.S., D.Phil., Organizers Monday, 14
July, 10:30 - 12:30 Last
updated 05 May 2009
Course Description: This two-hour course will provide an introduction to how radiologists can become
involved in the emerging role of MR in drug-development. Examples of applications in
the development of drugs for a variety of diseases will be reviewed.
Educational Objectives: Upon completion of this session, participants should be able to:
Identify
the key objectives of an MR study in development of a given drug; Explain why MR methodology studies (e.g.,
reproducibility, validation) should precede deployment of MR in clinical trials of novel
therapy; Recommend MR protocols for use in drug development;
explain how and why these differ from protocols used in routine diagnostic practice; Recognize the impact of Good Clinical Practice
regulations in the MR study, and advise physicist and physician co-workers accordingly.
Monday, 14 July
David S. Lester and Steve C.R.
Williams, Moderators
10:30
The Emerging Role of MR in Drug
Development
John C. Waterton
10:50
Imaging and Neurological Drug
Development
Douglas L.
Arnold
11:10
Imaging and Cardiovascular Drug
Development
Chun Yuan
11:30
Imaging and Oncologic Drug
Development
Teresa McShane
11:50
Imaging and Arthritis Drug
Development
Charles G. Peterfy
12:10
What Radiologists Need to Know
About Roles and Rules in Clinical MR Trials
Identify
the key objectives of an MR study in development of a given drug;